Patents by Inventor Patrick Schnider
Patrick Schnider has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11964986Abstract: The present invention relates to 9-oxo-9,10-dihydro-6H-pyrano[3,2-b:4,5-b?]dipyridine-8-carboxylic acid derivatives, their manufacture, pharmaceutical compositions containing them and their use as a medicament.Type: GrantFiled: July 3, 2023Date of Patent: April 23, 2024Assignee: REJUVERON TELOMERE THERAPEUTICS AGInventors: Patrick Schnider, Fedor Romanov Michailidis, Chien-Chi Hsiao
-
Publication number: 20230202990Abstract: The invention provides novel compounds having the general formula I wherein R1, R2 and R3 are as defined herein, compositions including the compounds and methods of using the compounds as V1a receptor modulators for treatment of conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior, social anxiety disorder, post-traumatic stress disorder (PTSD), brain edema in stroke or traumatic brain injury, and phase shift sleep disorders such as jetlagType: ApplicationFiled: January 20, 2023Publication date: June 29, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo DOLENTE, Guido GALLEY, Patrick SCHNIDER
-
Publication number: 20230167127Abstract: The invention provides novel compounds having the general formula (1) wherein R1, R2, R3, R3b, R4, A1, A2, A3, A4, A5, A6, B1, B2, B3, B4, and L are as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: September 23, 2022Publication date: June 1, 2023Applicant: Hoffmann-La Roche Inc.Inventors: John G. CUMMING, Christian KRAMER, Lukas KREIS, Holger KUEHNE, Patrick SCHNIDER
-
Publication number: 20230150995Abstract: The invention provides novel compounds having the general formula I wherein R and X are as defined herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: January 20, 2023Publication date: May 18, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Guido GALLEY, Patrick SCHNIDER
-
Publication number: 20230106150Abstract: The present invention provides spiro-oxazolones, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The present compounds are useful as therapeutics acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.Type: ApplicationFiled: November 29, 2022Publication date: April 6, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Valerie Runtz-Schmitt, Patrick Schnider, Cosimo Dolente, Bernhard Fasching
-
Patent number: 11578077Abstract: The present invention provides spiro-oxazolones, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The present compounds are useful as therapeutics acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.Type: GrantFiled: October 8, 2019Date of Patent: February 14, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Valerie Runtz-Schmitt, Patrick Schnider, Cosimo Dolente, Bernhard Fasching
-
Publication number: 20220306607Abstract: The present invention provides compounds of formula I wherein R1, R2 or R3 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.Type: ApplicationFiled: June 1, 2022Publication date: September 29, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Bjoern Bartels, Amanda Lee Dupont, Benjamin J. Hall, Jean-Yves Wach, Christian Schnider, Patrick Schnider, Michael Reutllinger, Eoin O'Connor, Eva Katrin Harde, Michael Weber
-
Publication number: 20200039997Abstract: The present invention provides spiro-oxazolones, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The present compounds are useful as therapeutics acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.Type: ApplicationFiled: October 8, 2019Publication date: February 6, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Valerie Runtz-Schmitt, Patrick Schnider, Cosimo Dolente, Bernhard Fasching
-
Patent number: 10479796Abstract: The present invention provides spiro-oxazolones, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The present compounds are useful as therapeutics acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.Type: GrantFiled: June 6, 2016Date of Patent: November 19, 2019Assignee: Hoffman-La Roche Inc.Inventors: Valerie Runtz-Schmitt, Patrick Schnider, Cosimo Dolente, Bernhard Fasching
-
Patent number: 10265327Abstract: This invention relates to a new medical use for certain chemical compounds and pharmaceutical compositions containing them. The invention relates to compounds which are selective V1a antagonists for use in the treatment of phase shift sleep disorders, in particular jetlag. In another aspect, the invention relates to a pharmaceutical composition for use in the treatment of phase shift sleep disorders comprising a compound according to the invention and a pharmaceutically acceptable carrier.Type: GrantFiled: March 9, 2016Date of Patent: April 23, 2019Assignee: Hoffmann-La Roche Inc.Inventors: Patrick Schnider, Christophe Grundschober
-
Patent number: 10092551Abstract: Spiro-thiazolones of formula I wherein X1, X2, X3, X4, R2, R3, R4, R5, R6 and R7 are as defined herein, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments for treatment of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.Type: GrantFiled: May 10, 2017Date of Patent: October 9, 2018Assignee: Hoffmann-LaRoche Inc.Inventors: Cosimo Dolente, Bernhard Fasching, Valerie Runtz-Schmitt, Patrick Schnider
-
Publication number: 20180064727Abstract: This invention relates to a new medical use for certain chemical compounds and pharmaceutical compositions containing them. The invention relates to compounds which are selective V1a antagonists for use in the treatment of phase shift sleep disorders, in particular jetlag. In another aspect, the invention relates to a pharmaceutical composition for use in the treatment of phase shift sleep disorders comprising a compound according to the invention and a pharmaceutically acceptable carrier.Type: ApplicationFiled: March 9, 2016Publication date: March 8, 2018Applicant: Hoffmann-La Roche Inc.Inventors: Patrick Schnider, Christophe Grundschober
-
Patent number: 9828385Abstract: The present invention provides spiro-oxazolones, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The present compounds are useful as therapeutics acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.Type: GrantFiled: August 18, 2016Date of Patent: November 28, 2017Assignee: Hoffmann-La Roche Inc.Inventors: Cosimo Dolente, Bernhard Fasching, Valerie Runtz-Schmitt, Patrick Schnider
-
Publication number: 20170246153Abstract: Spiro-thiazolones of formula I wherein X1, X2, X3, X4, R2, R3, R4, R5, R6 and R7 are as defined herein, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments for treatment of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.Type: ApplicationFiled: May 10, 2017Publication date: August 31, 2017Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo Dolente, Bernhard Fasching, Valerie Schmitt, Patrick Schnider
-
Publication number: 20170008901Abstract: The present invention provides spiro-oxazolones, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The present compounds are useful as therapeutics acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.Type: ApplicationFiled: June 6, 2016Publication date: January 12, 2017Applicant: Hoffmann-La Roche Inc.Inventors: Valerie Runtz-Schmitt, Patrick Schnider, Cosimo Dolente, Bernhard Fasching
-
Publication number: 20160355522Abstract: The present invention provides spiro-oxazolones, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The present compounds are useful as therapeutics acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.Type: ApplicationFiled: August 18, 2016Publication date: December 8, 2016Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo Dolente, Bernhard Fasching, Valerie Runtz-Schmitt, Patrick Schnider
-
Patent number: 9346824Abstract: The present invention provides 4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.Type: GrantFiled: April 4, 2014Date of Patent: May 24, 2016Assignee: Hoffman-La Roche, Inc.Inventors: Cosimo Dolente, Patrick Schnider
-
Patent number: 8828989Abstract: The present invention provides 4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes of the formula wherein R1 and R2 are as defined herein and which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments.Type: GrantFiled: August 23, 2012Date of Patent: September 9, 2014Assignee: Hoffmann-La Roche Inc.Inventors: Cosimo Dolente, Patrick Schnider
-
Publication number: 20140221350Abstract: The present invention provides 4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.Type: ApplicationFiled: April 4, 2014Publication date: August 7, 2014Applicant: HOFFMANN-LA ROCHE INC.Inventors: Cosimo Dolente, Patrick Schnider
-
Patent number: 8664216Abstract: The present invention is concerned with spiro-dihydrotetraazabenzoazulenes, i.e. spiro-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulenes of formula I wherein R1, R2, R3, X, Y, Z, m and n are as described herein. The compounds according to the invention act as V1a receptor modulators and are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.Type: GrantFiled: November 6, 2009Date of Patent: March 4, 2014Assignee: Hoffmann-La Roche Inc.Inventors: Caterina Bissantz, Erwin Goetschi, Roland Jakob-Roetne, Raffaello Masciadri, Emmanuel Pinard, Hasane Ratni, Mark Rogers-Evans, Patrick Schnider